Published in Biochem Biophys Res Commun on January 03, 2013
Trends in purchases and intake of foods and beverages containing caloric and low-calorie sweeteners over the last decade in the United States. Pediatr Obes (2013) 1.12
Wnt/β-catenin signaling plays an ever-expanding role in stem cell self-renewal, tumorigenesis and cancer chemoresistance. Genes Dis (2016) 0.97
Blood flow suppresses vascular Notch signalling via dll4 and is required for angiogenesis in response to hypoxic signalling. Cardiovasc Res (2013) 0.94
Notch signaling: its roles and therapeutic potential in hematological malignancies. Oncotarget (2016) 0.87
Molecular profiling of childhood cancer: Biomarkers and novel therapies. BBA Clin (2014) 0.86
Aberrant activation of Wnt/β-catenin signaling drives proliferation of bone sarcoma cells. Oncotarget (2015) 0.85
ΔNp63α enhances the oncogenic phenotype of osteosarcoma cells by inducing the expression of GLI2. BMC Cancer (2014) 0.83
Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies. Stem Cells Int (2016) 0.81
Germline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy. Nat Rev Endocrinol (2017) 0.80
Whole exome sequencing of a single osteosarcoma case--integrative analysis with whole transcriptome RNA-seq data. Hum Genomics (2014) 0.79
Doxorubicin activates the Notch signaling pathway in osteosarcoma. Oncol Lett (2015) 0.78
β-Catenin transcriptional activity is minimal in canine osteosarcoma and its targeted inhibition results in minimal changes to cell line behaviour. Vet Comp Oncol (2013) 0.78
MiR-367 negatively regulates apoptosis induced by adriamycin in osteosarcoma cells by targeting KLF4. J Bone Oncol (2016) 0.77
Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance. Chin J Cancer (2016) 0.77
Down regulation of Wnt signaling mitigates hypoxia-induced chemoresistance in human osteosarcoma cells. PLoS One (2014) 0.77
Anoikis-resistant subpopulations of human osteosarcoma display significant chemoresistance and are sensitive to targeted epigenetic therapies predicted by expression profiling. J Transl Med (2015) 0.76
High Expression of XRCC6 Promotes Human Osteosarcoma Cell Proliferation through the β-Catenin/Wnt Signaling Pathway and Is Associated with Poor Prognosis. Int J Mol Sci (2016) 0.75
Role of Topoisomerases in Pediatric High Grade Osteosarcomas: TOP2A Gene Is One of the Unique Molecular Biomarkers of Chemoresponse. Cancers (Basel) (2013) 0.75
Overexpression of miR-506 suppresses proliferation and promotes apoptosis of osteosarcoma cells by targeting astrocyte elevated gene-1. Oncol Lett (2016) 0.75
Estrogen-related receptor alpha confers methotrexate resistance via attenuation of reactive oxygen species production and P53 mediated apoptosis in osteosarcoma cells. Biomed Res Int (2014) 0.75
Antitumor Activity of 3-Indolylmethanamines 31B and PS121912. Anticancer Res (2015) 0.75
Deciphering signaling networks in osteosarcoma pathobiology. Exp Biol Med (Maywood) (2016) 0.75
Repression of Wnt/β-catenin response elements by p63 (TP63). Cell Cycle (2016) 0.75
TRIM37 promotes tumor cell proliferation and drug resistance in pediatric osteosarcoma. Oncol Lett (2017) 0.75
Downregulation of calbindin 1, a calcium-binding protein, reduces the proliferation of osteosarcoma cells. Oncol Lett (2017) 0.75
Wnt Signaling in Ewing Sarcoma, Osteosarcoma, and Malignant Peripheral Nerve Sheath Tumors. Curr Osteoporos Rep (2017) 0.75
Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev (2008) 2.74
Osteosarcoma. Ann Oncol (2010) 2.30
Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J Pathol (2010) 2.17
Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest (2009) 2.09
Therapy for osteosarcoma: where do we go from here? Paediatr Drugs (2008) 1.95
Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res (2004) 1.93
Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol (2010) 1.92
CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res (2010) 1.78
Osteosarcoma. J Am Acad Orthop Surg (2009) 1.73
Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol (2007) 1.70
Retracted Critical role of notch signaling in osteosarcoma invasion and metastasis. Clin Cancer Res (2008) 1.61
Notch signaling contributes to the pathogenesis of human osteosarcomas. Hum Mol Genet (2009) 1.56
Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation. Br J Cancer (2009) 1.49
Surgical options for children with osteosarcoma. Lancet Oncol (2005) 1.49
Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer (2004) 1.48
Regulation of NOTCH signaling by reciprocal inhibition of HES1 and Deltex 1 and its role in osteosarcoma invasiveness. Oncogene (2010) 1.38
Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma. Mol Cancer Ther (2010) 1.37
The multidisciplinary management of osteosarcoma. Curr Treat Options Oncol (2009) 1.37
Appraising the current role of chemotherapy for the treatment of sarcoma. Semin Oncol (2011) 1.28
The Wnt signaling pathway: implications for therapy in osteosarcoma. Expert Rev Anticancer Ther (2011) 1.23
Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. Lancet Oncol (2010) 1.22
Cytoplasmic and/or nuclear staining of beta-catenin is associated with lung metastasis. Clin Exp Metastasis (2003) 1.19
Targeted mutation of p53 and Rb in mesenchymal cells of the limb bud produces sarcomas in mice. Carcinogenesis (2009) 1.15
Identification of potential chemoresistance genes in osteosarcoma. Anticancer Res (2008) 1.06
Alteration of Notch signaling in skeletal development and disease. Ann N Y Acad Sci (2010) 1.04
Role of GLI2 in the growth of human osteosarcoma. J Pathol (2011) 0.99
Stratifying osteosarcoma: minimizing and maximizing therapy. Curr Oncol Rep (2010) 0.90
How can survival be improved in localized osteosarcoma? Expert Rev Anticancer Ther (2010) 0.87
Effect of the Hedgehog-inhibitor cyclopamine on mice with osteosarcoma pulmonary metastases. Int J Mol Med (2011) 0.86
Inhibition of osteosarcoma cell proliferation by the Hedgehog-inhibitor cyclopamine. J Chemother (2007) 0.85
The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span. Development (2004) 5.27
With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging. Cell Metab (2010) 4.11
Inhibition of mRNA translation extends lifespan in Caenorhabditis elegans. Aging Cell (2007) 3.78
Activation of beta-catenin signaling in articular chondrocytes leads to osteoarthritis-like phenotype in adult beta-catenin conditional activation mice. J Bone Miner Res (2009) 3.61
Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest (2002) 3.29
MicroRNA-204 regulates Runx2 protein expression and mesenchymal progenitor cell differentiation. Stem Cells (2010) 3.16
Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res (2006) 3.10
Overview of image-guided radiation therapy. Med Dosim (2006) 3.07
Novel Schiff base copper complexes of quinoline-2 carboxaldehyde as proteasome inhibitors in human prostate cancer cells. J Med Chem (2006) 2.90
Corrosion at the head-neck taper as a cause for adverse local tissue reactions after total hip arthroplasty. J Bone Joint Surg Am (2012) 2.86
A multicenter retrieval study of the taper interfaces of modular hip prostheses. Clin Orthop Relat Res (2002) 2.78
Dmp1-deficient mice display severe defects in cartilage formation responsible for a chondrodysplasia-like phenotype. J Biol Chem (2004) 2.70
Synovial fluid biomarkers for periprosthetic infection. Clin Orthop Relat Res (2010) 2.48
E3 ubiquitin ligase Smurf1 mediates core-binding factor alpha1/Runx2 degradation and plays a specific role in osteoblast differentiation. J Biol Chem (2003) 2.34
Runx2-mediated regulation of the zinc finger Osterix/Sp7 gene. Gene (2006) 2.16
Results of unicompartmental knee arthroplasty at a minimum of ten years of follow-up. J Bone Joint Surg Am (2005) 2.14
Remodeling of cortical bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapy. Nat Med (2005) 2.10
Periosteal progenitor cell fate in segmental cortical bone graft transplantations: implications for functional tissue engineering. J Bone Miner Res (2005) 2.04
Generation of a transgenic mouse model with chondrocyte-specific and tamoxifen-inducible expression of Cre recombinase. Genesis (2007) 2.01
Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. Ann Med (2006) 1.97
Tumor necrosis factor promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts. J Biol Chem (2005) 1.96
Adverse local tissue reaction arising from corrosion at the femoral neck-body junction in a dual-taper stem with a cobalt-chromium modular neck. J Bone Joint Surg Am (2013) 1.95
Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice. Arthritis Rheum (2004) 1.94
A multinational assessment of metal-on-metal bearings in hip replacement. J Bone Joint Surg Am (2011) 1.90
The biology of the growth plate. J Bone Joint Surg Am (2003) 1.89
Bone morphogenetic protein receptor signaling is necessary for normal murine postnatal bone formation. J Cell Biol (2002) 1.88
Rapid rehabilitation and recovery with minimally invasive total hip arthroplasty. Clin Orthop Relat Res (2004) 1.86
COX-1 and COX-2 expression in osteoid osteomas. J Orthop Res (2002) 1.84
Preoperative testing for sepsis before revision total knee arthroplasty. J Arthroplasty (2007) 1.83
RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis. J Bone Miner Res (2004) 1.83
The BMP signaling and in vivo bone formation. Gene (2005) 1.82
Smurf1 inhibits osteoblast differentiation and bone formation in vitro and in vivo. J Biol Chem (2003) 1.81
Inhibition of beta-catenin signaling in articular chondrocytes results in articular cartilage destruction. Arthritis Rheum (2008) 1.77
Two year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of disease. J Rheumatol (2003) 1.77
Experimental and clinical performance of porous tantalum in orthopedic surgery. Biomaterials (2006) 1.77
Applications of porous tantalum in total hip arthroplasty. J Am Acad Orthop Surg (2006) 1.76
RBPjkappa-dependent Notch signaling regulates mesenchymal progenitor cell proliferation and differentiation during skeletal development. Development (2010) 1.72
Modes of wear after semiconstrained total elbow arthroplasty. J Bone Joint Surg Am (2008) 1.71
Biologic effects of implant debris. Bull NYU Hosp Jt Dis (2009) 1.69
Beta-catenin and BMP-2 synergize to promote osteoblast differentiation and new bone formation. J Cell Biochem (2005) 1.69
Conditional activation of β-catenin signaling in mice leads to severe defects in intervertebral disc tissue. Arthritis Rheum (2012) 1.67
Inhibition of beta-catenin signaling causes defects in postnatal cartilage development. J Cell Sci (2008) 1.67
Genetic inhibition of fibroblast growth factor receptor 1 in knee cartilage attenuates the degeneration of articular cartilage in adult mice. Arthritis Rheum (2012) 1.66
ALK2 functions as a BMP type I receptor and induces Indian hedgehog in chondrocytes during skeletal development. J Bone Miner Res (2003) 1.66
Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One (2012) 1.63
Use of polymerase chain reaction to diagnose tuberculous arthritis from joint tissues and synovial fluid. Arch Pathol Lab Med (2004) 1.63
Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells. Breast Cancer Res (2005) 1.60
Ten-year outcome of serum metal ion levels after primary total hip arthroplasty: a concise follow-up of a previous report*. J Bone Joint Surg Am (2013) 1.60
A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent. Cancer Res (2007) 1.59
A perspective: engineering periosteum for structural bone graft healing. Clin Orthop Relat Res (2008) 1.57
Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood (2003) 1.56
Serum metal levels and bearing surfaces in total hip arthroplasty. J Arthroplasty (2006) 1.56
Chondrocyte BMP2 signaling plays an essential role in bone fracture healing. Gene (2012) 1.56
Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo. Int J Cancer (2009) 1.55
Efficacy and safety of an intraoral electrostimulation device for xerostomia relief: a multicenter, randomized trial. Arthritis Rheum (2011) 1.54
Regulation of chondrogenesis and chondrocyte differentiation by stress. J Clin Invest (2008) 1.53
Murine and chicken chondrocytes regulate osteoclastogenesis by producing RANKL in response to BMP2. J Bone Miner Res (2008) 1.53
Revision total knee arthroplasty: 1990 through 2002. A review of the Finnish arthroplasty registry. J Bone Joint Surg Am (2006) 1.52
Results of giant cell tumor of bone treated with intralesional excision. Clin Orthop Relat Res (2004) 1.50
Biological effects of rAAV-caAlk2 coating on structural allograft healing. Mol Ther (2005) 1.49
A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts. Cancer Res (2006) 1.48
Outcome of prosthesis exchange for infected knee arthroplasty: the effect of treatment approach. Acta Orthop (2009) 1.48
Increased expression and processing of ADAM 12 (meltrin-alpha) in osteolysis associated with aseptic loosening of total hip replacement implants. J Rheumatol (2005) 1.46
Wnt induction of chondrocyte hypertrophy through the Runx2 transcription factor. J Cell Physiol (2006) 1.46
Intraoral electrostimulator for xerostomia relief: a long-term, multicenter, open-label, uncontrolled, clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol (2012) 1.46
Soluble and particulate Co-Cr-Mo alloy implant metals activate the inflammasome danger signaling pathway in human macrophages: a novel mechanism for implant debris reactivity. J Orthop Res (2009) 1.45
The zinc finger transcription factor Gli2 mediates bone morphogenetic protein 2 expression in osteoblasts in response to hedgehog signaling. Mol Cell Biol (2006) 1.45
Cyclin D1-cdk4 induce runx2 ubiquitination and degradation. J Biol Chem (2006) 1.45
Lymphocyte responses in patients with total hip arthroplasty. J Orthop Res (2005) 1.44
The progression of patellofemoral arthrosis after medial unicompartmental replacement: results at 11 to 15 years. Clin Orthop Relat Res (2004) 1.44
Smad6 interacts with Runx2 and mediates Smad ubiquitin regulatory factor 1-induced Runx2 degradation. J Biol Chem (2005) 1.44
BMP2, but not BMP4, is crucial for chondrocyte proliferation and maturation during endochondral bone development. J Cell Sci (2011) 1.44
Professionalism in publishing. J Bone Joint Surg Am (2006) 1.43
Loosening and osteolysis associated with metal-on-metal bearings: A local effect of metal hypersensitivity? J Bone Joint Surg Am (2006) 1.43
Inflammatory immune cell responses and Toll-like receptor expression in synovial tissues in rheumatoid arthritis patients treated with biologics or DMARDs. Clin Rheumatol (2013) 1.42
Ubiquitin ligase Smurf1 mediates tumor necrosis factor-induced systemic bone loss by promoting proteasomal degradation of bone morphogenetic signaling proteins. J Biol Chem (2008) 1.41
Corneal innervation and morphology in primary Sjögren's syndrome. Invest Ophthalmol Vis Sci (2003) 1.41
External beam radiation therapy for orthopaedic pathology. J Am Acad Orthop Surg (2015) 1.41
NOTCH signaling in skeletal progenitors is critical for fracture repair. J Clin Invest (2016) 1.41
Structural bone allograft combined with genetically engineered mesenchymal stem cells as a novel platform for bone tissue engineering. Tissue Eng (2007) 1.41
Life span extension via eIF4G inhibition is mediated by posttranscriptional remodeling of stress response gene expression in C. elegans. Cell Metab (2011) 1.39
Preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Am Acad Orthop Surg (2011) 1.39
The orthopaedic genome: what does the future hold and are we ready? J Bone Joint Surg Am (2002) 1.39
Smad3-deficient chondrocytes have enhanced BMP signaling and accelerated differentiation. J Bone Miner Res (2005) 1.39
Hierarchical three-dimensional ZnCo₂O₄ nanowire arrays/carbon cloth anodes for a novel class of high-performance flexible lithium-ion batteries. Nano Lett (2012) 1.39
Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer. Cancer Res (2007) 1.39
Wnt/β-catenin signaling activates bone morphogenetic protein 2 expression in osteoblasts. Bone (2012) 1.38
Etk/Bmx as a tumor necrosis factor receptor type 2-specific kinase: role in endothelial cell migration and angiogenesis. Mol Cell Biol (2002) 1.37
Incidence of prosthetic joint infections after primary knee arthroplasty. J Arthroplasty (2008) 1.37
Smad4 is required for maintaining normal murine postnatal bone homeostasis. J Cell Sci (2007) 1.37